Open AccessSurvival of the Fittest: Hypomethylating Agent/BCL-2 Inhibitor Combination Versus Intensive Chemotherapy As Frontline Treatment for Acute Myeloid Leukemia
Author(s) -
Michael J. Hochman,
Robert P. Hasserjian
Publication year - 2022
Publication title -
the hematologist
Language(s) - English
Resource type - Journals
ISSN - 1551-8779
DOI - 10.1182/hem.v19.2.202228
Subject(s) - myeloid leukemia , hypomethylating agent , medicine , chemotherapy , oncology , myeloid , leukemia , biology , gene , genetics , dna methylation , gene expression